Qubit Pharmaceuticals key facts
as of Oct 2026- Developer of a drug discovery simulation platform designed to reduce the cost and length of preclinical drug development.
- Qubit Pharmaceuticals is valued at approximately $48.1M as of Oct 2026 (last reported valuation).
- It has raised $28.7M; the latest was Later Stage VC ($2.3M) in Oct 2025.
- Notable investors include European Innovation Council, La French Tech, XAnge, Omnes Capital, Audacia — 11 tracked in total.
- Status: Privately Held (backing).
Qubit Pharmaceuticals's last reported valuation, Jun 2022. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Qubit Pharmaceuticals: the Monday email on marks, rounds and moves
Qubit Pharmaceuticals funding rounds
No funding rounds for Qubit Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Qubit Pharmaceuticals
11+Qubit Pharmaceuticals valuation
Qubit Pharmaceuticals's last reported valuation was $48.1 million in Jun 2022. No priced round, secondary trade or fund mark has surfaced since.
Qubit Pharmaceuticals investors
11 investors are on record for Qubit Pharmaceuticals, including European Innovation Council, La French Tech, XAnge and Omnes Capital.
About Qubit Pharmaceuticals
Developer of a drug discovery simulation platform designed to reduce the cost and length of preclinical drug development. The company's platform uses proprietary force field models and molecular dynamics calculations, performs virtual screening and visualization to find valuable candidates, enabling biopharmaceutical companies to get support in their research and development by accelerating drug discovery with quantum physics.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2020
- Employees
- 71
- Website
- qubit-pharmaceuticals.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.